Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israël, Tel Aviv
Ofer Merimsky
41 années d'expérience
accréditations :
La clinique est certifiée :
| Israël | Turquie | Espagne | |
| Thérapie par faisceau de protons | de $48,000 | de $70,000 | de $25,785 |
| Prostatectomie robotisée Da Vinci | de $24,570 | de $17,000 | de $10,000 |
| CyberCouteau | de $17,500 | de $4,750 | de $30,000 |
| Curiethérapie | de $14,200 | de $3,465 | de $10,000 |
| Chirurgie du cancer du poumon | de $27,500 | de $17,000 | de $40,000 |
Chef de l'unité d'oncologie des tissus mous et des os au centre médical Sourasky – Le Dr Merimsky est spécialisé dans les cas de sarcomes complexes.
Le Dr Pelles Sharon se spécialise dans les traitements avancés de l'adénocarcinome au centre médical Sourasky, incluant la CHIP et l'immunothérapie.
Le Dr Sarid est spécialisé en chimiothérapie et radiothérapie, avec plus de 25 ans d'expérience en oncologie au centre médical Sourasky (Ichilov), leader en Israël.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.